Patent · US Active

Use of a Janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms

US12391946B2 · kind B2 · utility

0Cited by
0References
15Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 3, 2020
Grant dateAug 19, 2025
Priority date—
Expiry dateJan 18, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2310/3515
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Aspects of the disclosure include methods for treating a myeloproliferative neoplasm. Methods according to certain embodiments include co-administering to a subject a Janus kinase (JAK) inhibitor and a telomerase inhibitor comprising an oligonucleotide and a lipid moiety linked to the 5′ and/or 3′ end of the oligonucleotide. Methods for inducing apoptosis of a myeloproliferative neoplasm cell by contacting the cell with an amount of a JAK inhibitor and a telomerase inhibitor sufficient to induce apoptosis are also described. Compositions having a JAK inhibitor and a telomerase inhibitor for practicing the subject methods are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.